Sign In
Buy MIST
$1.28
-0.0400 (-3.03%)
At Close: Jun 03, 2026
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
07:15am, Monday, 13'th May 2024
– NDA for etripamil in PSVT resubmitted in 1Q 2024 – Cash resources as of March 31, 2024 expected to fund operations into 2026 – Dialogue with FDA to finalize Phase 3 protocol for etripamil
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
08:00am, Wednesday, 17'th Apr 2024
MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innova
Data from this large safety-trial also published in The Journal of the American College of Cardiology Data from this large safety-trial also published in The Journal of the American College of Cardiol
MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innova
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
07:14am, Thursday, 21'st Mar 2024
- On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeti
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
04:01pm, Thursday, 29'th Feb 2024
MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a corporate pan
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants
07:00am, Thursday, 29'th Feb 2024
MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commerci
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
04:37pm, Wednesday, 28'th Feb 2024
MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commerci
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
07:16pm, Monday, 22'nd Jan 2024
NEW YORK , Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") (NASDAQ: MIST). Such investors
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround
11:26am, Tuesday, 16'th Jan 2024
Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street anal
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
11:45am, Sunday, 14'th Jan 2024
NEW YORK, Jan. 14, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") (NASDAQ: MIST). Such investors
NEW YORK , Jan. 7, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Milestone Pharmaceuti
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
11:15am, Saturday, 06'th Jan 2024
NEW YORK , Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") (NASDAQ: MIST). Such investors
NEW YORK , Dec. 30, 2023 /PRNewswire/ -- WHY: New York, N.Y., December 30, 2023.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
11:02am, Thursday, 28'th Dec 2023
NEW YORK , Dec. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") (NASDAQ: MIST). Such investor
